Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration.
According to the terms of the agreement, DWTI is slated to receive an upfront technology access fee and research support from Glaukos. If any of the candidate compounds are identified, Glaukos has exclusive rights to develop intracameral and topical products through a licensing deal with DWTI, the companies reported.
“We are delighted to enter into this collaboration with D. Western, which has a proven track record of novel drug discovery and is highly regarded in the industry as the preeminent research organization for proprietary ROCK inhibitor compounds,” Thomas Burns, Glaukos president & CEO, said in prepared remarks.
“We are excited to commence the initial phases of this collaborative research effort to explore potential new compounds that may be used in our novel iDose drug delivery system in order to expand and improve the treatment of glaucoma,” Burns added.